Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$21.66 USD
-1.08 (-4.75%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $21.78 +0.12 (0.55%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 581 - 600 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Publication of EXPAREL Cost- Savings Solidifies Its Use in A Multi-Modal Post-Op Pain Management System. Reiterate OUTPERFORM and $98 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Data for May Suggests to Us That EXPAREL Sales Growth Continues into Q2. Reiterate OUTPERFORM and $98 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
June and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Data for April Suggests to Us That EXPAREL Sales Growth Continues into Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Data for April Suggests to Us That EXPAREL Sales Growth Continues into Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Nerve Block sNDA Submitted to The FDA; March 5, 2015 PDUFA Anticipated. Reiterate OUTPERFORM and $98 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Nerve Block sNDA Submitted to The FDA; March 5, 2015 PDUFA Anticipated. Reiterate OUTPERFORM and $98 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
ANOTHER EXPAREL BEAT IN Q1 IS HARBINGER OF MORE; MAINTAIN BUY
Provider: NATIONAL ALLIANCE CAPITAL MARKETS
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: Strong EXPAREL Sales Lead to H2 Breakeven & Long-Term Growth; Reiterate OUTPERFORM and Increase PT to $98 due to a 5% Price Increase
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Preview and March Symphony Health Estimates: No Surprises Following $34.4MM Q1 Exparel Sales Preannouncement; Reiterate OUTPERFORM and $92 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Preview and March Symphony Health Estimates: No Surprises Following $34.4MM Q1 Exparel Sales Preannouncement; Reiterate OUTPERFORM and $92 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Corporate Update: Pipeline, Regulatory, Manufacturing and Financing Progress; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
"SUITE C" MANUFACTURING EXPANSION APPROVED
Provider: NATIONAL ALLIANCE CAPITAL MARKETS
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Data Suggests to Us That Q1 EXPAREL Sales Are on Track; Reiterate OUTPERFORM and $92 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Data Suggests to Us That Q1 EXPAREL Sales Are on Track; Reiterate OUTPERFORM and $92 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L